

## Effect of *Clostridium butyricum* on fecal flora in *Helicobacter pylori* eradication therapy

Izumi Shimbo, Taketo Yamaguchi, Takeo Odaka, Kenichi Nakajima, Akinori Koide, Hidehiko Koyama, Hiromitsu Saisho

Izumi Shimbo, Taketo Yamaguchi, Takeo Odaka, Hiromitsu Saisho, Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 260-0856, Japan  
Kenichi Nakajima, Tako Chuo Hospital, Tako-machi Katori-Country, Chiba, 289-2241, Japan  
Akinori Koide, Kawasaki Chiba Hospital, Minami-cho, Chuo-ku, Chiba-City, Chiba, 260-0842, Japan  
Hidehiko Koyama, International University of Health and Welfare, Mita Hospital, Mita Minato-ku Tokyo, 108-8329, Japan  
Co-first-authors: Izumi Shimbo, and Taketo Yamaguchi  
Co-correspondents: Taketo Yamaguchi  
Correspondence to: Yamaguchi, PhD, Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 260-0856, Japan. yama.takeo@faculty.chiba-u.jp  
Telephone: +81-43-226-2083 Fax: +81-43-226-2088  
Received: 2005-04-27 Accepted: 2005-06-02

### Abstract

**AIM:** To investigate the effect of probiotic bacterium, *Clostridium butyricum* MIYAIRI 588 strain (CBM) on the changes of the fecal flora in *Helicobacter pylori* (*H pylori*) treatment.

**METHODS:** Thirty-five patients with gastric or duodenal ulcers positive for *H pylori* were randomized either to 1 wk amoxicillin, clarithromycin, lansoprazole (Group 1) or to the same regimen supplemented with CBM 7 d ahead of the triple therapy (Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d after the starting eradication therapy, and were examined intestinal flora. Patients were required to keep a diary record of their condition.

**RESULTS:** Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group 1. On the other hand, they did not decrease significantly in Group 2. The *Escherichia coli* was dominant bacterium in *Enterobacteriaceae*, but that was replaced by other species such as *Klebsiella* and *Enterobacter* after eradication in Group 1. The change was suppressed in Group 2. Abdominal symptoms were less frequent in Group 2 than in Group 1.

**CONCLUSION:** The combined use of CBM reduced the changes in the intestinal flora and decreased the incidence of gastrointestinal side effects.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

**Key words:** *Clostridium butyricum*; Intestinal flora; *Helicobacter pylori*; Eradication

Shimbo I, Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, Saisho H. Effect of *Clostridium butyricum* on fecal flora in *Helicobacter pylori* eradication therapy. *World J Gastroenterol* 2005; 11(47): 7520-7524  
<http://www.wjgnet.com/1007-9327/11/7520.asp>

### INTRODUCTION

Antibiotic therapy causes loose stools and/or diarrhea quite frequently, probably because of changes in the intestinal flora. Super infection arising from the alterations of the normal intestinal flora is a factor in the onset of infectious enteritis.

*Helicobacter pylori* (*H pylori*) is deeply involved in gastroduodenal ulcer disease and *H pylori*-positive patients are generally treated with antibiotics to eradicate this bacterium<sup>[1]</sup>. Triple therapy with a proton pump inhibitor and two antibiotics selected from among the following three: amoxicillin, clarithromycin and metronidazole, is now considered to be the standard therapy, and it is reported that a bacterial eradication rate of about 80-90% can be achieved<sup>[2-4]</sup>. Although such therapy causes few serious adverse reactions, gastrointestinal side effects like diarrhea and loose stools occur at a high incidence<sup>[5]</sup>.

It is known that probiotic supplementation prevents or reduces of antibiotics-induced diarrhea. Recent studies have shown that probiotics were effective against gastrointestinal symptoms associated with *H pylori* eradication therapy<sup>[6]</sup>. Probiotics are defined as viable microorganisms which, when ingested, have a beneficial effect on human health, including amelioration or prevention of specific pathologic conditions<sup>[7]</sup>.

*Clostridium butyricum* is a butyric acid producing Gram-positive anaerobe which is found in soil and the intestines of healthy animals and humans, and the MIYAIRI 588 strain of *C. butyricum* (CBM) has been used as probiotics for treating and preventing non-antimicrobial induced diarrhea, antimicrobial associated diarrhea and constipation in human beings<sup>[8-10]</sup>. MIYA-BM<sup>®</sup> tablets (Miyarisan pharmaceutical Co., Ltd., Tokyo, Japan) containing CBM were approved from Japanese Ministry of Health and




Figure 1 Study design. Fecal sample collection(↓).

Welfare for human clinical use since 1970 in Japan.

However, the preventive effect of CBM preparation on the abnormalities of intestinal microflora due to *H. pylori* eradication therapy was unknown. Therefore, in the present study, we have examined the changes of fecal flora and gastrointestinal symptoms frequently during *H. pylori* eradication therapy, and evaluated the utility of CBM supplementation to prevent the disturbance of the intestinal flora.

## MATERIALS AND METHODS

### Patients

Of the patients diagnosed as having gastric or duodenal ulcers at the outpatient clinic of the First Department of Medicine of Chiba University, 35 patients (male/female: 28/7; mean age  $52.7 \pm 11.3$  years) were enrolled in this study. They were all positive for *H. pylori* by culture method, microscopical examination and the rapid urease test (PyloriTek<sup>®</sup> test kit, Serim Research Corp., Elkhart, IN, USA).

The patients were blindly and randomly allocated to two groups. Seventeen patients were assigned the 1 wk triple therapy consisting of amoxicillin 1 500 mg b.i.d., clarithromycin 400 mg b.i.d. and lansoprazole 60 mg b.i.d. (Group 1). Alternatively, eighteen were assigned to the same regimen supplemented with CBM (120 mg t.i.d.), which was started 1 wk prior to the eradication therapy for 14 d (Group 2). The patients had not been treated with any drugs that might have influenced intestinal bacteria, and had no known underlying gastrointestinal disorders. They were all given a full explanation of the contents of the study and they provided their informed consent in writing.

Six weeks after the completion of the therapy, the <sup>13</sup>C-urea breath test was performed to check whether eradication had been achieved.

### Collection of stool samples

Stool samples were collected the day before the start of the therapy, and on d 2, 4, 8, 15, and 22 after the start of *H. pylori* eradication therapy in Group 1. In Group 2, stools were also collected 1 wk after the administration of CBM (Figure 1). Fresh samples were placed in a transporter filled with CO<sub>2</sub> (Kenkiporter<sup>®</sup> II, Clinical Supply, Gifu, Japan), and were transferred under refrigeration for culture within 24 h of the collection.

### Examination of intestinal flora

Intestinal flora was investigated according to Mitsuoka's method<sup>[8]</sup>. Any bacterium detected was identified at the level of species or genus, and counted. The microorganisms were classified into sub groups of bacteria according to morphology of the colonies, Gram staining and cell shapes. Isolation of *Clostridium difficile* was also attempted.

The nonselective media used for isolation included TS, EG, and BL agar, while selective media included DHL, TATAC, P, PEES, LBS, NBGT, ES, BS, and CCMA agar. A stool sample (0.5 g) was placed into an anaerobic glove box (N<sub>2</sub> 80%, H<sub>2</sub> 10%, CO<sub>2</sub> 10%) and was diluted with a diluent for anaerobic bacteria from 10-fold to 10<sup>8</sup>-fold in 10 steps. Aliquots (0.05 mL) of each dilution were cultured anaerobically in an incubator in the glove box at 37 °C for 3 d. When TS, DHL, TATAC, P, or PEES agar was used the culture plates were removed from the glove box after the bacteria were seeded and were cultured aerobically at 37 °C for 1 to 2 d. Any colony that grew during anaerobic culture was also examined for aerobic growth. Smears were prepared on slide glasses for any colony that grew and the smears were subjected to Gram staining for microscopic observation. Then each organism was classified on the basis of its characteristics, including colony morphology, growth under aerobic conditions, and growth in selective culture media. The number of live bacteria of each genus per 1 g of feces was calculated from the number of colonies and converted into a logarithmic equivalent for each bacterial species identified; log colony forming unit/g feces (logCFU/g feces). The detection limit was 2.3 logCFU/g feces. The total count of viable bacteria was calculated from the sum of the counts of each bacterial species. Species in the Enterobacteriaceae were identified by the kit of Enterotube<sup>®</sup> II (Becton Dickinson, USA).

### Assessment of symptoms

Each patient was required to keep a daily record of the conditions of their stools and any abdominal symptoms, from before the therapy to 2 wk after the completion of *H. pylori* eradication therapy.

### Statistical analysis

Bacterial counts were expressed as the mean  $\pm$  SD. Statistical evaluation of changes within groups was carried out using the Wilcoxon signed-rank test. The Mann-Whitney *U* test was used for comparison between groups. Fisher's exact test was performed to compare the detection rates. Differences of  $P < 0.05$  were considered to be statistically significant.

## RESULTS

### Intestinal flora before *H. pylori* eradication therapy

The levels of obligate and facultative anaerobes in the groups did not differ significantly. The predominant bacteria were obligate anaerobes, such as Bacteroidaceae,

**Table 1** Level of obligate and facultative anaerobes in Group1 and Group2, before *H pylori* eradication therapy (mean±SD)

| Population            | LogCFU/g         |                  |
|-----------------------|------------------|------------------|
|                       | Group 1 (n = 17) | Group 2 (n = 18) |
| Total counts          | 10.4±0.4         | 10.2±0.5         |
| Obligate anaerobes    | 10.4±0.4         | 10.2±0.6         |
| Bacteroidaceae        | 10.1±0.4 (100)   | 9.3±1.6 (100)    |
| Bifidobacteria        | 9.8±0.6 (93.8)   | 9.6±0.6 (93.8)   |
| Peptococci            | 8.9±0.8 (62.5)   | 9.0±0.5 (62.5)   |
| Clostridia            | 7.5±1.9 (93.8)   | 7.9±1.5 (100)    |
| Micrococci            | 3.0±1.2 (25)     | 3.5±1.8 (37.5)   |
| Facultative anaerobes | 8.3±0.7          | 8.1±1.0          |
| Enterobacteriaceae    | 7.2±1.7 (93.8)   | 6.7±1.5 (100)    |
| <i>E.coli</i>         | 7.3±1.4 (81.3)   | 6.4±1.6 (93.8)   |
| Others                | 6.9±1.8 (18.8)   | 5.7±1.0 (31.3)   |
| Enterococci           | 7.3±1.1 (93.8)   | 7.9±1.0 (93.8)   |
| Lactobacilli          | 7.2±1.6 (100)    | 6.9±1.0 (93.8)   |
| Bacilli               | 7.6±0.9 (37.5)   | 7.4±0.6 (25)     |
| Yeasts                | 5.0±2.0 (75)     | 4.8±1.8 (56.3)   |

There are no significant differences between the two groups using Mann-Whitney *U* test. Figures in parentheses are detection rates.

**Table 2** Detection rates of fecal flora

| Population                | Group | Detection rates (%) |                   |                    |                   |                   |      |
|---------------------------|-------|---------------------|-------------------|--------------------|-------------------|-------------------|------|
|                           |       | Before              | D2                | D4                 | D8                | D15               | D22  |
| <i>Bacteroidaceae</i>     | 1     | 100                 | 100               | 93.8               | 100               | 100               | 93.3 |
|                           | 2     | 100                 | 94.4              | 100                | 100               | 100               | 94.4 |
| <i>Bifidobacteria</i>     | 1     | 93.8                | 62.5 <sup>a</sup> | 50.0 <sup>b</sup>  | 62.5 <sup>a</sup> | 68.8              | 73.3 |
|                           | 2     | 93.8                | 66.7              | 44.4 <sup>b</sup>  | 72.2              | 66.7              | 66.7 |
| <i>Clostridia</i>         | 1     | 93.8                | 93.8              | 75                 | 100               | 100               | 100  |
|                           | 2     | 100                 | 94.4              | 94.4               | 94.4              | 100               | 100  |
| <i>Enterobacteriaceae</i> | 1     | 93.8                | 93.8              | 100                | 93.8              | 100               | 100  |
|                           | 2     | 100                 | 94.4              | 100                | 94.4              | 100               | 100  |
| <i>E.coli</i>             | 1     | 81.3                | 62.5              | 25                 | 37.5 <sup>a</sup> | 87.5              | 93.3 |
|                           | 2     | 93.8                | 72.2              | 94.4               | 66.7 <sup>b</sup> | 88.9              | 77.8 |
| Others                    | 1     | 18.8                | 75.0 <sup>b</sup> | 81.3 <sup>d</sup>  | 75                | 81.3 <sup>d</sup> | 46.7 |
|                           | 2     | 31.3                | 27.8              | 16.7               | 38.9              | 33.3              | 50   |
| <i>Enterococci</i>        | 1     | 93.8                | 87.5              | 81.3               | 100               | 100               | 100  |
|                           | 2     | 93.8                | 100               | 100                | 100               | 100               | 100  |
| <i>Lactobacilli</i>       | 1     | 100                 | 87.5              | 68.8 <sup>a</sup>  | 43.8 <sup>d</sup> | 93.8              | 93.3 |
|                           | 2     | 93.8                | 61.1 <sup>a</sup> | 61.1 <sup>a</sup>  | 44.4 <sup>b</sup> | 100               | 88.9 |
| Yeasts                    | 1     | 75                  | 93.8              | 100.0 <sup>a</sup> | 93.8              | 87.5              | 86.7 |
|                           | 2     | 56.3                | 61.1              | 72.2               | 83.3              | 44.4              | 66.7 |

<sup>a</sup>*P*<0.05, <sup>b</sup>*P*<0.01, <sup>d</sup>*P*<0.001 vs before, Fisher's exact test.


Bifidobacteria and in both groups (Table 1). As for the viable counts and detection rates of all species, there was not significant difference between the two groups. The viable counts and detection rates of all species did not change significantly between before and 1 wk after CBM administration in Group 2 (data not shown). None of the patients was positive for *C. difficile* as assessed by culture.

**Counts of CBM and detection rate**

Counts of CBM increased and averaged 6.7 logCFU/g on the day before eradication therapy. The detection rate was

**Table 3** Clinical symptoms observed during and after *H pylori* eradication therapy

|                      | Group 1 (n = 17, %) |        | Group 2 (n = 18, %) |        |
|----------------------|---------------------|--------|---------------------|--------|
| Loose stool          | 8                   | (47.1) | 4                   | (22.2) |
| Water diarrhea       | 2                   | (11.8) | 1                   | (5.6)  |
| Abdominal pain       | 2                   | (11.8) | 0                   | (0)    |
| Abdominal distention | 2                   | (11.8) | 0                   | (0)    |



**Figure 2** Obligate anaerobes during and after *H pylori* eradication therapy There are no significant differences between the two groups before therapy. Statistically significant changes are noted as <sup>a</sup>*P*<0.05, <sup>b</sup>*P*<0.01 before using the Wilcoxon's signed-rank test.

the highest on d 2 (90%); it gradually decreased. On d 15, CBM became under detectable.

**Intestinal flora after starting *H pylori* eradication therapy**

Obligate anaerobes decreased significantly on d 2, 4, 8, and 15, and returned to their pretreatment levels on d 22 in Group 1. On the other hand, the number of obligate anaerobes did not change significantly at any time in Group 2 (Figure 2). The number of facultative anaerobes did not decrease significantly in either group.

The detection rates of intestinal flora are shown in Table 2. Bacteroidaceae, the dominant bacteria, did not change after starting eradication of *H pylori* in either group. *Bifidobacterium* was significantly lower on d 2, 4, and 8 in Group 1, in the other, only on d 4 in Group 2. As for each group of facultative anaerobes, *E.coli* was significantly lower on d 4, 8 and other species such as *Klebsiella* and *Enterobacter* in Enterobacteriaceae were significantly higher on d 2, 4, 8, and 15 in Group 1. On the other hand, either Enterobacteriaceae did not change significantly in Group 2. Lactobacilli significantly lower in either group.

Yeasts was significantly higher on d 4 in Group 1. No significant alterations in Yeasts were observed in Group 2. All bacterial groups recovered to pretreatment levels d 22 after completion of the drug administration. No patients were colonized with *C.difficile* at any time.



### Clinical symptoms

As for abdominal symptoms, in Group 1, loose stools were noted in 8 of 17 patients (47.1%); diarrhea in 2 of 17 patients (11.8%); abdominal pain and distention in 2 of 17 patients (11.8%), each. In Group 2, loose stools were noted in 4 of 18 patients (22.2%) and diarrhea in 1 of 17 patients (5.6%). The rates were lower in Group 2, although the differences were not significant (Table 3). Treatment was successful in 13 out of 17 patients in Group 1 (76.5%) and in 17 out of 18 patients in Group 2 (94.4%).

## DISCUSSION

The intestinal flora in our subjects before the treatment was similar to that detected in normal adults by Mitsuoka<sup>[11]</sup>. It is known that the normal fecal flora is almost the same as that of the recto-sigmoid colon. Intestinal flora is reported to remain stable in each individual, although it differs among individuals<sup>[12-13]</sup>. However, it has been shown that the administration of antimicrobial agents, which are excreted in the bile, in the intestinal mucosa or are incompletely absorbed, causes changes in the normal intestinal flora.

Buhling *et al.*<sup>[14]</sup> have shown that infrequent detection of Clostridia, Veillonella, Eubacteria, Actinomyces, Bifidobacteria and E.coli with simultaneous more frequent growth of other Enterobacteria and Yeasts on d 8 of starting *H pylori* treatment, and after 4 wk of therapy, the microflora returned to normal.

When they collected stool samples for three times (d 0, 8, 35-40), we examined the chronological changes of the intestinal flora were followed 6 or 7 times at short intervals during and after *H pylori* treatment in this study.

Then we found that the total bacterial counts started to decrease as early as on d 2 of therapy. Especially, obligate anaerobes, which are the dominant bacteria, were markedly reduced. And it took 3 wk for them to return to their pretreatment levels after starting of therapy.

These bacteria are known to produce short-chain fatty acids (SCFA). Such SCFA are considered to promote proliferation of colonic epithelial cells, provide energy for colonic epithelial cells and to stimulate the absorption of water and sodium<sup>[15-19]</sup>.

Previous studies have demonstrated a close correlation between a decrease in the viable count of anaerobes and a reduction in SCFA content. The drastic reduction of intestinal SCFA associated with the decrease in anaerobes during the diarrheal stage and the increase of the pH thought to be due to these changes, result in increase of the fecal water content<sup>[20-22]</sup>.

Probiotics are known to prevent or lower the antibiotic-related gastrointestinal side effects. It is reported that CBM together with germinated barley foodstuff effectively increased the level of SCFA in feces and suppressed dextran sulfate sodium-induced experimental colitis in rats<sup>[23]</sup>. Butyric acids, which is produced by CBM has stronger stimulatory effects on epithelial cell proliferation than other SCFA, such as acetic acid or propionic acid<sup>[24]</sup>.

Tanaka *et al.*<sup>[25]</sup> reported that the effect of CBM

on the side effect of *H pylori* eradication triple therapy *in vivo*. These results have shown that obligate anaerobe and Lactobacillus decreased in the rat intestine and then SCFA in intestinal contents were decreased. However, administration of CBM preparation with *H pylori* eradication triple therapy was increased SCFA and resident fusiform bacteria in the mucous layer were more frequently observed in rats administered with CBM preparation than *H pylori* eradication triple therapy.

Our present findings show that CBM preparations prevent the decrease of obligate anaerobes and reduce the frequency of gastrointestinal side effects. These result similar to the previous *in vivo* result. However, we did not examine the concentration of SCFA in this study but it is possible that the one of mechanism of action of CBM preparation to prevent the side effect induced by not only maintenance of intestinal flora but also increased SCFA contents by CBM.

In our study, *H pylori* eradication therapy caused a significantly greater decrease of *E.coli*, as a results, Enterobacteriaceae, except of *E.coli*, such as *Klebsiella* and *Enterobacter* that are known to potential cause of diarrhea was rising in Group 1.

Our results showed that CBM suppressed the replacement of *E.coli* by other species in Enterobacteriaceae and superinfection.

In conclusion, intestinal flora with an eradication treatment of *H pylori* not a little changed. The change was reduced by supplementation of CBM, and the frequency of gastrointestinal side effects decreased. Furthermore CBM may have some beneficial effects on *H pylori* infection.

## ACKNOWLEDGMENT

We would like to express our gratitude to Mamoru Tanaka, Miyarisan pharmaceutical Co., Ltd. for his technical help.

## REFERENCES

- 1 Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. *Am J Kidney Dis* 1994; **24**: 159-171
- 2 Miwa H, Nagahara A, Sato K, Ohkura R, Murai T, Shimizu H, Watanabe S, Sato N. Efficacy of 1 week omeprazole or lansoprazole-amoxicillin-clarithromycin therapy for *Helicobacter pylori* infection in the Japanese population. *J Gastroenterol Hepatol* 1999; **14**: 317-321
- 3 Labenz J, Stolte M, Peitz U, Tillenburg B, Becker T, Börsch G. One-week triple therapy with omeprazole, amoxicillin and either clarithromycin or metronidazole for cure of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1996; **10**: 207-210
- 4 Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, Fedorak R, Bazzoli F, Hentschel E, Mora P, Archimandritis A, Megraud F. Short-course therapy with amoxicillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates *Helicobacter pylori* and heals duodenal ulcer. *ACT-10 Study Group. Aliment Pharmacol Ther* 1997; **11**: 943-952
- 5 Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idstrom JP. Eradication of *Helicobacter pylori* using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. *Helicobacter* 1996; **1**: 138-144

- 6 **Armuzzi A**, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, Gasbarrini G, Gasbarrini A. The effect of oral administration of *Lactobacillus* GG on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther* 2001; **15**: 163-169
- 7 **Gorbach SL**. Lactic acid bacteria and human health. *Ann Med* 1990; **22**: 37-41
- 8 **Seki H**, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by *Clostridium butyricum* MIYAIRI. *Pediatr Int* 2003; **45**: 86-90
- 9 **Kamiya S**, Taguchi H, Yamaguchi H, Osaki T, Takahashi M, Nakamura S. Bacterioprophyllaxis using *Clostridium butyricum* for lethal caecitis by *Clostridium difficile*. *Rev. Med. Microbiol.* 1997; **8**: S57-S59.
- 10 **Okamoto T**, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of *Clostridium butyricum* M588 in dextran sodium sulfate-induced colitis in rats. *J Gastroenterol* 2000; **35**: 341-346
- 11 **Mitsuoka T**. Cultivation of intestinal bacteria. In: Mitsuoka T, ed. *Intestinal bacteria and health*. Tokyo: Harcourt Brace Jovanovich Japan;1978.19-36.
- 12 **Sanders WE**, Sanders CC. Modification of Normal Flora by Antibiotics: Effects on Individuals and the Environment. In: Root RK, Sande MA, eds. *New dimensions in antimicrobial therapy*. New York: Churchill Livingstone, 1984:217-41
- 13 **Simon GL**, Gorbach SL. The human intestinal microflora. *Dig Dis Sci* 1986; **31**: 147S-162S
- 14 **Bühling A**, Radun D, Müller WA, Malfertheiner P. Influence of anti-*Helicobacter* triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. *Aliment Pharmacol Ther* 2001; **15**: 1445-1452
- 15 **Sakata T**, von Engelhardt W. Stimulatory effect of short chain fatty acids on the epithelial cell proliferation in rat large intestine. *Comp Biochem Physiol A Comp Physiol* 1983; **74**: 459-462
- 16 **Roediger WE**. Utilization of nutrients by isolated epithelial cells of the rat colon. *Gastroenterology* 1982; **83**: 424-429
- 17 **Ruppin H**, Bar-Meir S, Soergel KH, Wood CM, Schmitt MG. Absorption of short-chain fatty acids by the colon. *Gastroenterology* 1980; **78**: 1500-1507
- 18 **Koruda MJ**, Rolandelli RH, Settle RG, Saul SH, Rombeau JL. Harry M. Vars award. The effect of a pectin-supplemented elemental diet on intestinal adaptation to massive small bowel resection. *JPEN J Parenter Enteral Nutr* 1986; **10**: 343-350
- 19 **Crump MH**, Argenzio RA, Whipp SC. Effects of acetate on absorption of solute and water from the pig colon. *Am J Vet Res* 1980; **41**: 1565-1568
- 20 **Tazume S**, Ozawa A, Yamamoto T, Takahashi Y, Takeshi K, Saidi SM, Ichoroh CG, Waiyaki PG. Ecological study on the intestinal bacteria flora of patients with diarrhea. *Clin Infect Dis* 1993; **16 Suppl 2**: S77-S82
- 21 **Fujita K**, Kaku M, Yanagase Y, Ezaki T, Furuse K, Ozawa A, Saidi SM, Sang WK, Waiyaki PG. Physicochemical characteristics and flora of diarrhoeal and recovery faeces in children with acute gastro-enteritis in Kenya. *Ann Trop Paediatr* 1990; **10**: 339-345
- 22 **Takahashi M**, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. The effect of probiotic treatment with *Clostridium butyricum* on enterohemorrhagic *Escherichia coli* O157:H7 infection in mice. *FEMS Immunol Med Microbiol* 2004; **41**: 219-226
- 23 **Araki Y**, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T. The dietary combination of germinated barley foodstuff plus *Clostridium butyricum* suppresses the dextran sulfate sodium-induced experimental colitis in rats. *Scand J Gastroenterol* 2000; **35**: 1060-1067
- 24 **Kripke SA**, Fox AD, Berman JM, Settle RG, Rombeau JL. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. *JPEN J Parenter Enteral Nutr* 1989; **13**: 109-116
- 25 **Tanaka M**, Miyagawa N, Tsutsumi Y. Preventive effect of *Clostridium butyricum* on the side effect of the *Helicobacter pylori* eradication. *Chin J Gastroenterol* 2000; **5**: Suppl A116